Clinical Trial Update: Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) [Phase 2]

View source ↗

Summary

This document reports the withdrawal of a Phase 2 trial evaluating avelumab in combination with tuvusertib for advanced urothelial carcinoma that progressed aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Tuvusertib (tuvusertib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN